Navigation path

Calls for proposals

The 3rd Call FP7 published - Deadline: 03 December 2008 at 17:00:00 (Brussels local time)
Subscribe to our mailing list to receive up-to-date information.

Anti-microbial drug resistance including fungal pathogens

The strategic objective of this area is to confront the increasing emergence and spread of antimicrobial drug resistant pathogens in Europe and the rest of the world at broad fronts and in a multi-disciplinary approach through the development of effective infection prevention and control strategies. Focus will be on combining basic research on molecular mechanisms of resistance, microbial ecology and host-pathogen interactions with clinical research towards new interventions.

Expected impact: Reinforced research integration of European excellence in the field of antimicrobial drug resistance will be targeted towards a set of clearly defined objectives with the following expected impact: in a first attempt to address the fundamental questions of antimicrobial resistance at the global scale, an appreciation of the scale, nature and variability of the problem will be made possible and new strategies for controlling resistance in different parts of the world proposed. By studying the longterm impact of different antibiotics on the human host, it will, for the first time, be possible to weigh the clinical benefits of various antibiotic therapeutic interventions against their possible side-effects at the level of the individual patient. A feed-back system for clinical evaluation of new point-of-care diagnostic and susceptibility tests will accelerate and economise the implementation of diagnostic tests in the clinical setting, necessary to support for optimised prescription of anti-infective drugs.
Topics for single-stage submission and evaluation; deadline 3 December 2008:

HEALTH-2009-2.3.1-1: Global collaborative research on the prevention of antibiotic resistance. FP7-HEALTH-2009-single-stage.

The aim is to establish global collaboration of research and training in order to develop regionally adapted and cost-effective measures to prevent the emergence and spread of antibiotic resistance. Research objectives should include, but are not limited to, the development of a global map of bacterial clonality, resistance phenotypes, resistance genes and their mobile genetic elements, the correlation of antibiotic resistance with antibiotic consumption in various geographical regions, the association of risk factors for the spread of antibiotic resistance and the establishment of mathematical models for prediction of future resistance trends in different parts of the world. The active participation of partners from ICPC countries could add to the scientific and/or technological excellence of the project and/or lead to an increased impact of the research to be undertaken.

Funding scheme: Collaborative Project (Large scale integrating project).

HEALTH-2009-2.3.1-2: Impact of specific antibiotic therapies on the prevalence of resistant bacteria in the human host. FP7-HEALTH-2009-single-stage.

The objective is to develop a multidisciplinary approach bridging bacterial genetics, clinical, and pharmacological research in order to study the impact of different existing antibiotics in selecting resistance. Research should envisage intervention studies, including randomised controlled trials, studies on the dynamics, transmission, and the biological cost of antibiotic resistance as well as an in-depth analysis of resistance mechanisms and their dissemination utilising state-of-the-art molecular techniques.

Funding scheme: Collaborative Project (Small or medium-scale focused research project).

HEALTH-2009-2.3.1-3: Clinical evaluation of point-of-care diagnostic tests for microbial detection and identification, antibiotic susceptibility determination and biomarkers. FP7-HEALTH-2009-single-stage.

The objective is to address the current gap between technological advances and the actual clinical needs for optimised prescription of antibiotics by setting up an integrated tool for evaluation of new point-of-care diagnostic tests in the nosocomial and/or primary care setting. Evaluation criteria should include simplicity, sensitivity, specificity, reliability, speed, robustness, user-friendliness and cost-effectiveness. Projects should ensure that results of the clinical evaluation are fed back to the biotechnology sector and manufacturers of diagnostic tests. Social, ethical, environmental and economic (including cost/benefit) hurdles to the implementation of novel diagnostic tests into healthcare programmes should also be identified and a map-gap analysis of priority diseases for which current diagnostic options are particularly poor should be performed. The end-result should be a roadmap for research, development and efficient uptake of rapid diagnostics for patient benefit in Europe.

Funding scheme: Collaborative Project (Small or medium-scale focused research project).

For more information